These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38706271)

  • 41. Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia.
    Grothe MJ; Schuster C; Bauer F; Heinsen H; Prudlo J; Teipel SJ
    J Neurol; 2014 Oct; 261(10):1939-48. PubMed ID: 25059393
    [TBL] [Abstract][Full Text] [Related]  

  • 42. White matter hyperintensities on MRI in dementia with Lewy bodies, Parkinson's disease with dementia, and Alzheimer's disease.
    Joki H; Higashiyama Y; Nakae Y; Kugimoto C; Doi H; Kimura K; Kishida H; Ueda N; Nakano T; Takahashi T; Koyano S; Takeuchi H; Tanaka F
    J Neurol Sci; 2018 Feb; 385():99-104. PubMed ID: 29406924
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.
    Wilcock D; Jicha G; Blacker D; Albert MS; D'Orazio LM; Elahi FM; Fornage M; Hinman JD; Knoefel J; Kramer J; Kryscio RJ; Lamar M; Moghekar A; Prestopnik J; Ringman JM; Rosenberg G; Sagare A; Satizabal CL; Schneider J; Seshadri S; Sur S; Tracy RP; Yasar S; Williams V; Singh H; Mazina L; Helmer KG; Corriveau RA; Schwab K; Kivisäkk P; Greenberg SM;
    Alzheimers Dement; 2021 Apr; 17(4):704-715. PubMed ID: 33480172
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A multiparametric MRI study of structural brain damage in dementia with lewy bodies: A comparison with Alzheimer's disease.
    Caso F; Agosta F; Scamarcia PG; Basaia S; Canu E; Magnani G; Volontè MA; Filippi M
    Parkinsonism Relat Disord; 2021 Oct; 91():154-161. PubMed ID: 34628194
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe.
    Harding AJ; Broe GA; Halliday GM
    Brain; 2002 Feb; 125(Pt 2):391-403. PubMed ID: 11844739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population.
    McDougall F; Edgar C; Mertes M; Delmar P; Fontoura P; Abi-Saab D; Lansdall CJ; Boada M; Doody R
    J Prev Alzheimers Dis; 2021; 8(2):151-160. PubMed ID: 33569561
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuropsychological Impairments and Their Cognitive Architecture in Mild Cognitive Impairment (MCI) with Lewy Bodies and MCI-Alzheimer's Disease.
    Ciafone J; Thomas A; Durcan R; Donaghy PC; Hamilton CA; Lawley S; Roberts G; Colloby S; Firbank MJ; Allan L; Petrides G; Taylor JP; O'Brien JT; Gallagher P
    J Int Neuropsychol Soc; 2022 Oct; 28(9):963-973. PubMed ID: 34666864
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cingulate island sign on FDG-PET is associated with medial temporal lobe atrophy in dementia with Lewy bodies.
    Iizuka T; Kameyama M
    Ann Nucl Med; 2016 Jul; 30(6):421-9. PubMed ID: 27098829
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of Kami-guibi-tang for mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled trial.
    Shin HY; Kim HR; Jahng GH; Jin C; Kwon S; Cho SY; Park SU; Jung WS; Moon SK; Ko CN; Park JM
    BMC Complement Med Ther; 2021 Oct; 21(1):251. PubMed ID: 34620151
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multimodal EEG-MRI in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies.
    Colloby SJ; Cromarty RA; Peraza LR; Johnsen K; Jóhannesson G; Bonanni L; Onofrj M; Barber R; O'Brien JT; Taylor JP
    J Psychiatr Res; 2016 Jul; 78():48-55. PubMed ID: 27060340
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dementia with Lewy bodies.
    McKeith IG; Burn DJ; Ballard CG; Collerton D; Jaros E; Morris CM; McLaren A; Perry EK; Perry R; Piggott MA; O'Brien JT
    Semin Clin Neuropsychiatry; 2003 Jan; 8(1):46-57. PubMed ID: 12567332
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 55. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up.
    Bonanni L; Thomas A; Tiraboschi P; Perfetti B; Varanese S; Onofrj M
    Brain; 2008 Mar; 131(Pt 3):690-705. PubMed ID: 18202105
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial.
    Querfurth HW; Allam GJ; Geffroy MA; Schiff HB; Kaplan RF
    Dement Geriatr Cogn Disord; 2000; 11(6):314-21. PubMed ID: 11044776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cholinesterase inhibitors for dementia with Lewy bodies.
    Wild R; Pettit T; Burns A
    Cochrane Database Syst Rev; 2003; 2003(3):CD003672. PubMed ID: 12917981
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dementia with Lewy bodies: reclassification of pathological subtypes and boundary with Parkinson's disease or Alzheimer's disease.
    Iseki E
    Neuropathology; 2004 Mar; 24(1):72-8. PubMed ID: 15068176
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cognitive Decline in Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease: A Prospective Cohort Study.
    Hamilton CA; Matthews FE; Donaghy PC; Taylor JP; O'Brien JT; Barnett N; Olsen K; Lloyd J; Petrides G; McKeith IG; Thomas AJ
    Am J Geriatr Psychiatry; 2021 Mar; 29(3):272-284. PubMed ID: 32863138
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
    Wessels AM; Dowsett SA; Sims JR
    J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.